Literature DB >> 6975640

Platelet von Willebrand's antigen II: active release by aggregating agents and a marker of platelet release reaction in vivo.

J P Scott, R R Montgomery.   

Abstract

von Willebrand's antigen II (vW AgII), a plasma and platelet antigen immunologically and biochemically distinct from factor-VIII-related antigen (VIIIR:Ag), is decreased in von Willebrand's disease. vW AgII is released from platelets during aggregation and clotting. The release of platelet vW AgII was studied in washed platelets following aggregation by thrombin, collagen, and adenosine diphosphate (ADP). Total platelet vW AgII was 3.39 U/10(9) platelets. Thrombin and collagen yielded release of 85% and 86% of platelet vW AgII, respectively, at the highest concentrations. Release of platelet vW AgII was correlated with the release of 5-hydroxytryptamine (5HT). Release of vW AgII by collagen and thrombin was inhibited by metabolic inhibitors. In addition, collagen release of vW AgII was inhibited by aspirin. In clinical syndromes associated with intravascular platelet destruction, marked elevations of plasma vW AgII were noted. Thus, vW AgII is released by a metabolically active process from platelets during aggregation. In addition, vW AgII appears to be a marker of intravascular platelet destruction.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6975640

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  von Willebrand factor propeptide: biology and clinical utility.

Authors:  Sandra L Haberichter
Journal:  Blood       Date:  2015-07-27       Impact factor: 22.113

2.  Interaction of von Willebrand factor with human platelets in the plasma milieu.

Authors:  J Schullek; J Jordan; R R Montgomery
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

3.  Endothelial cell synthesis of von Willebrand antigen II, von Willebrand factor, and von Willebrand factor/von Willebrand antigen II complex.

Authors:  D R McCarroll; E G Levin; R R Montgomery
Journal:  J Clin Invest       Date:  1985-04       Impact factor: 14.808

4.  Divergent fates of von Willebrand factor and its propolypeptide (von Willebrand antigen II) after secretion from endothelial cells.

Authors:  D D Wagner; P J Fay; L A Sporn; S Sinha; S O Lawrence; V J Marder
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

5.  Full-length von Willebrand factor (vWF) cDNA encodes a highly repetitive protein considerably larger than the mature vWF subunit.

Authors:  C L Verweij; P J Diergaarde; M Hart; H Pannekoek
Journal:  EMBO J       Date:  1986-08       Impact factor: 11.598

6.  A novel mouse model of type 2N VWD was developed by CRISPR/Cas9 gene editing and recapitulates human type 2N VWD.

Authors:  Qizhen Shi; Scot A Fahs; Jeremy G Mattson; Hongyin Yu; Crystal L Perry; Patricia A Morateck; Jocelyn A Schroeder; Jessica Rapten; Hartmut Weiler; Robert R Montgomery
Journal:  Blood Adv       Date:  2022-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.